Skip to content

Adiponectin and Inflammatory Mediators in Mediastinal Adipose Tissues

Adiponectin and Inflammatory Mediators in Mediastinal Adipose Tissues Between Patients With Coronary Artery Diseases and With Valvular Diseases

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01176357
Enrollment
60
Registered
2010-08-06
Start date
2008-01-31
Completion date
Unknown
Last updated
2010-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Coronary Artery Disease

Keywords

Coronary artery disease (CAD), atherosclerosis, mediastinal adipose tissue, adiponectin, inflammatory mediators

Brief summary

Coronary artery disease (CAD), the most common type of heart disease, is caused by hardening of the arteries, or atherosclerosis that is an inflammatory process in which immune mechanisms interact with metabolic risk factors to initiate, propagate, and activate lesions in the arterial trees. Epidemiological studies have found that increased cardiovascular risks are associated with increased levels of inflammatory cytokines (eg, interleukin-6 \[IL-6\] and tumor necrosis factor-alpha\[TNF-alpha\]) or their hepatic product, C-reactive protein (CRP). Higher expression of interleukin-Ibeta(IL-1beta),IL-6, monocyte chemotactic protein-1 (MCP-1), and TNF-alpha were observed in epicardial adipose tissues in patients with CAD. These findings suggested that the pericoronary tissues could be a source of inflammatory mediators or act as paracrine that lead to vascular inflammation on CAD pathogenesis. However, adiponectin, a kind of adipocytokine, produced and secreted exclusively by adipose tissue, has been reported to have a variety of anti-inflammatory functions against atherosclerosis, resulting in risk reduction for incidence of CAD events. It remains unclear whether adiponectin and inflammatory mediators in mediastinal adipose tissue contribute to CAD. We therefore aim to analyze the expression of adiponectin and inflammatory mediators in mediastinal adipose tissue between patients with CAD and with valve diseases, and to correlate these parameters with clinical atherosclerotic risks, medications (statins or antiplatelet), and blood sugar.

Interventions

None listed

Sponsors

Far Eastern Memorial Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patient underwent CABG or valve surgery in our hospital will be included

Exclusion criteria

* liver disease * dhronic renal insufficiency * neoplastic diseases * taking steroids * congestive heart failure

Countries

Taiwan

Contacts

Primary ContactKuan-Ming Chiu, MD, PhD
886-2-89667000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026